LAB
Standard BioTools Inc.
Price Chart
Latest Quote
$0.74
-0.01 (-1.71%)
Current Price
| Previous Close | $0.75 |
| Open | $0.77 |
| Day High | $0.80 |
| Day Low | $0.73 |
| Volume | 2,985,844 |
Stock Information
| Shares Outstanding | 391.46M |
| Total Debt | $29.49M |
| Cash Equivalents | $455.18M |
| Revenue | $86.25M |
| Net Income | $-50.08M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $289.72M |
| EPS (TTM) | $-0.13 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-131.74M |
| Sales | $86.25M |
| Income | $-50.08M |
| Book/sh | $1.44 |
| Cash/sh | $1.16 |
| Employees | 385 |
Financial Ratios
| Quick Ratio | 11.77 |
| Current Ratio | 12.36 |
| Debt/Eq | 5.26 |
Returns & Margins
| ROA | -8.05% |
| ROE | -9.86% |
| Gross Margin | 53.27% |
| Operating Margin | -44.53% |
| Profit Margin | 90.67% |
Ownership
| Insider Ownership | 1.46% |
| Institutional Ownership | 76.65% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -74.01 |
| P/S | 3.36 |
| P/B | 0.51 |
Analyst Data
| Recommendation | none |
| Target Price | $1.55 |
Technical Indicators
| SMA20 | $0.95 |
| SMA50 | $0.96 |
| SMA200 | $1.19 |
| RSI | 18.83 |
| ATR | 0.0960 |
| Shares Float | 210.32M |
| Short Float | 5.56% |
| Short Ratio | 5.93 |
| Volatility | 1.38 |
| Rel Volume | 0.69 |
Performance History
| Week | -8.63% |
| Month | -32.10% |
| Quarter | -22.91% |
| 6 Months | -55.95% |
| YTD | -41.72% |
| Year | -39.34% |
| 3 Years | -63.18% |
| 5 Years | -87.93% |
| 10 Years | -91.52% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $0.74 | 2,985,844 |
| 2026-06-24 | $0.75 | 4,618,300 |
| 2026-06-23 | $0.79 | 4,706,500 |
| 2026-06-22 | $0.77 | 1,830,100 |
| 2026-06-18 | $0.83 | 3,287,700 |
| 2026-06-17 | $0.81 | 2,036,000 |
| 2026-06-16 | $0.83 | 2,340,300 |
| 2026-06-15 | $0.85 | 1,892,800 |
| 2026-06-12 | $0.89 | 1,750,200 |
| 2026-06-11 | $0.91 | 2,328,800 |
| 2026-06-10 | $0.88 | 5,583,600 |
| 2026-06-09 | $0.89 | 8,350,000 |
| 2026-06-08 | $0.80 | 18,291,200 |
| 2026-06-05 | $1.15 | 3,499,600 |
| 2026-06-04 | $1.27 | 3,867,400 |
| 2026-06-03 | $1.14 | 3,616,900 |
| 2026-06-02 | $1.16 | 3,885,500 |
| 2026-06-01 | $1.15 | 2,375,600 |
| 2026-05-29 | $1.15 | 7,020,900 |
| 2026-05-28 | $1.14 | 2,174,100 |
| 2026-05-27 | $1.06 | 1,292,400 |
| 2026-05-26 | $1.09 | 2,317,300 |
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
đ° Latest News
Stealthy startup Treeline plans a reverse merger
BioPharma Dive âĸ 2026-06-09T11:50:00Z
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-06T00:30:09Z
Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why
Insider Monkey âĸ 2026-04-14T05:29:27Z
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Motley Fool âĸ 2026-02-27T16:18:28Z
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
Motley Fool âĸ 2026-02-27T16:12:38Z
Standard BioTools: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-02-24T21:34:18ZStandard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago
Simply Wall St. âĸ 2026-01-24T13:39:07Z
Institutional owners may consider drastic measures as Standard BioTools Inc.'s (NASDAQ:LAB) recent US$96m drop adds to long-term losses
Simply Wall St. âĸ 2025-12-28T13:17:58Z
Penny Stocks To Watch In December 2025
Simply Wall St. âĸ 2025-12-01T12:05:23Z
Standard BioTools (LAB): Losses Continue While Low Price-to-Sales Spurs Value Debate
Simply Wall St. âĸ 2025-11-05T23:16:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $42,788,000 | $46,125,000 | $55,890,000 | $60,897,000 |
| Cost Of Revenue | $42,788,000 | $46,125,000 | $55,890,000 | $60,897,000 |
| Total Revenue | $85,331,000 | $91,008,000 | $106,340,000 | $97,948,000 |
| Operating Revenue | $85,331,000 | $91,008,000 | $106,340,000 | $96,166,000 |
| Expenses | ||||
| Interest Expense | $26,000 | $3,316,000 | $4,567,000 | $4,331,000 |
| Total Expenses | $178,636,000 | $178,014,000 | $169,379,000 | $200,564,000 |
| Other Income Expense | $-12,550,000 | $-20,274,000 | $-12,170,000 | $-88,207,000 |
| Other Non Operating Income Expenses | $4,394,000 | $-5,008,000 | $1,391,000 | $-14,537,000 |
| Net Non Operating Interest Income Expense | $9,153,000 | $16,883,000 | $1,005,000 | $-2,105,000 |
| Interest Expense Non Operating | $26,000 | $3,316,000 | $4,567,000 | $4,331,000 |
| Operating Expense | $135,848,000 | $131,889,000 | $113,489,000 | $139,667,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-58,826,000 | $-90,939,000 | $-74,656,000 | $-190,098,000 |
| Net Interest Income | $9,153,000 | $16,883,000 | $1,005,000 | $-2,105,000 |
| Interest Income | $9,179,000 | $20,199,000 | $5,572,000 | $2,226,000 |
| Normalized Income | $-48,524,048 | $-78,878,860 | $-63,942,810 | $-117,533,050 |
| Net Income From Continuing And Discontinued Operation | $-74,896,000 | $-138,885,000 | $-74,656,000 | $-190,098,000 |
| Total Operating Income As Reported | $-110,249,000 | $-127,485,000 | $-76,600,000 | $-116,205,000 |
| Net Income Common Stockholders | $-74,896,000 | $-184,899,000 | $-74,656,000 | $-190,098,000 |
| Net Income | $-74,896,000 | $-138,885,000 | $-74,656,000 | $-190,098,000 |
| Net Income Including Noncontrolling Interests | $-74,896,000 | $-138,885,000 | $-74,656,000 | $-190,098,000 |
| Net Income Discontinuous Operations | $-16,070,000 | $-47,946,000 | $0 | - |
| Net Income Continuous Operations | $-58,826,000 | $-90,939,000 | $-74,656,000 | $-190,098,000 |
| Pretax Income | $-96,702,000 | $-90,397,000 | $-74,204,000 | $-192,928,000 |
| Special Income Charges | $-16,944,000 | $-15,266,000 | $-13,561,000 | $-13,589,000 |
| Interest Income Non Operating | $9,179,000 | $20,199,000 | $5,572,000 | $2,226,000 |
| Operating Income | $-93,305,000 | $-87,006,000 | $-63,039,000 | $-102,616,000 |
| Gross Profit | $42,543,000 | $44,883,000 | $50,450,000 | $37,051,000 |
| Per Share | ||||
| Diluted EPS | $-0.20 | $-0.52 | $-0.94 | $-2.43 |
| Basic EPS | $-0.20 | $-0.52 | $-0.94 | $-2.43 |
| Other | ||||
| Tax Effect Of Unusual Items | $-6,642,048 | $-3,205,860 | $-2,847,810 | $-1,105,050 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-68,755,000 | $-54,954,000 | $-40,896,000 | $-99,900,000 |
| Total Unusual Items | $-16,944,000 | $-15,266,000 | $-13,561,000 | $-73,670,000 |
| Total Unusual Items Excluding Goodwill | $-16,944,000 | $-15,266,000 | $-13,561,000 | $-73,670,000 |
| Reconciled Depreciation | $10,977,000 | $16,861,000 | $15,180,000 | $15,027,000 |
| EBITDA (Bullshit earnings) | $-85,699,000 | $-70,220,000 | $-54,457,000 | $-173,570,000 |
| EBIT | $-96,676,000 | $-87,081,000 | $-69,637,000 | $-188,597,000 |
| Diluted Average Shares | $381,623,000 | $352,670,000 | $79,160,000 | $78,305,000 |
| Basic Average Shares | $381,623,000 | $352,670,000 | $79,160,000 | $78,305,000 |
| Diluted NI Availto Com Stockholders | $-74,896,000 | $-184,899,000 | $-74,656,000 | $-190,098,000 |
| Tax Provision | $-37,876,000 | $542,000 | $452,000 | $-2,830,000 |
| Restructuring And Mergern Acquisition | $16,944,000 | $15,266,000 | $13,561,000 | $13,589,000 |
| Research And Development | $25,987,000 | $28,831,000 | $25,948,000 | $37,382,000 |
| Selling General And Administration | $109,861,000 | $103,058,000 | $87,541,000 | $102,285,000 |
| Preferred Stock Dividends | - | $46,014,000 | - | - |
| Gain On Sale Of Security | - | - | - | $-60,081,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $424,291,000 | $471,722,000 | $-255,768,000 | $-200,318,000 |
| Total Assets | $567,754,000 | $612,345,000 | $323,067,000 | $390,310,000 |
| Total Non Current Assets | $113,490,000 | $236,462,000 | $164,852,000 | $181,495,000 |
| Other Non Current Assets | $3,154,000 | $186,982,000 | $2,285,000 | $3,109,000 |
| Non Current Deferred Assets | $38,628,000 | $138,000 | - | - |
| Non Current Deferred Taxes Assets | $38,628,000 | $138,000 | - | - |
| Current Assets | $454,264,000 | $375,883,000 | $158,215,000 | $208,815,000 |
| Other Current Assets | $4,871,000 | $4,561,000 | $3,127,000 | $4,278,000 |
| Assets Held For Sale Current | $228,406,000 | $42,963,000 | - | - |
| Inventory | $19,981,000 | $20,744,000 | $20,533,000 | $21,473,000 |
| Receivables | $13,431,000 | $14,741,000 | $19,660,000 | $17,280,000 |
| Accounts Receivable | $13,431,000 | $14,741,000 | $19,660,000 | $17,280,000 |
| Allowance For Doubtful Accounts Receivable | $-284,000 | $-260,000 | $-312,000 | $-592,000 |
| Gross Accounts Receivable | $13,715,000 | $15,001,000 | $19,972,000 | $17,872,000 |
| Cash Cash Equivalents And Short Term Investments | $187,575,000 | $292,874,000 | $114,895,000 | $165,784,000 |
| Cash And Cash Equivalents | $120,863,000 | $166,728,000 | $51,704,000 | $81,309,000 |
| Goodwill And Other Intangible Assets | - | $140,251,000 | $107,717,000 | $118,851,000 |
| Other Intangible Assets | - | $28,954,000 | $1,400,000 | $12,600,000 |
| Restricted Cash | - | - | - | $0 |
| Cash Equivalents | - | - | - | $53,894,000 |
| Cash Financial | - | - | - | $27,415,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $30,827,000 | $30,695,000 | $98,210,000 | $102,655,000 |
| Long Term Debt And Capital Lease Obligation | $25,337,000 | $25,889,000 | $34,357,000 | $96,890,000 |
| Long Term Debt | $299,000 | $299,000 | $3,983,000 | $62,809,000 |
| Current Debt And Capital Lease Obligation | $5,490,000 | $4,806,000 | $63,853,000 | $5,765,000 |
| Net Debt | - | - | $11,809,000 | - |
| Current Debt | - | - | $59,530,000 | $2,083,000 |
| Other Current Borrowings | - | - | $59,530,000 | $2,083,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $143,463,000 | $140,623,000 | $471,118,000 | $471,777,000 |
| Total Non Current Liabilities Net Minority Interest | $35,155,000 | $74,728,000 | $361,791,000 | $428,334,000 |
| Other Non Current Liabilities | $1,215,000 | $1,062,000 | $1,065,000 | $961,000 |
| Liabilities Heldfor Sale Non Current | $0 | $6,779,000 | - | - |
| Non Current Deferred Liabilities | $8,603,000 | $40,998,000 | $15,116,000 | $19,230,000 |
| Non Current Deferred Taxes Liabilities | $810,000 | $1,081,000 | $841,000 | $1,055,000 |
| Current Liabilities | $108,308,000 | $65,895,000 | $109,327,000 | $43,443,000 |
| Other Current Liabilities | $25,633,000 | $20,804,000 | - | - |
| Current Deferred Liabilities | $42,936,000 | $15,741,000 | $16,735,000 | $14,436,000 |
| Payables And Accrued Expenses | $16,103,000 | $14,504,000 | $16,687,000 | $19,277,000 |
| Payables | $5,407,000 | $5,049,000 | $10,061,000 | $9,088,000 |
| Accounts Payable | $5,407,000 | $5,049,000 | $9,236,000 | $7,914,000 |
| Interest Payable | - | $4,262,000 | $0 | - |
| Total Tax Payable | - | $1,581,000 | $825,000 | $1,174,000 |
| Equity | ||||
| Common Stock Equity | $424,291,000 | $471,722,000 | $-148,051,000 | $-81,467,000 |
| Total Equity Gross Minority Interest | $424,291,000 | $471,722,000 | $-148,051,000 | $-81,467,000 |
| Stockholders Equity | $424,291,000 | $471,722,000 | $-148,051,000 | $-81,467,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,492,000 | $1,225,000 | $-2,221,000 | $-1,896,000 |
| Other Equity Adjustments | $-1,492,000 | $1,225,000 | $-2,221,000 | $-1,896,000 |
| Retained Earnings | $-1,260,547,000 | $-1,185,651,000 | $-1,000,752,000 | $-926,096,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $311,253,000 | $311,253,000 |
| Other | ||||
| Treasury Shares Number | $18,580,000 | $18,580,000 | $3,132,000 | $422,000 |
| Ordinary Shares Number | $386,381,000 | $377,530,000 | $80,232,000 | $79,482,000 |
| Share Issued | $404,961,000 | $396,110,000 | $83,364,000 | $79,904,000 |
| Tangible Book Value | $424,291,000 | $471,722,000 | $-255,768,000 | $-200,318,000 |
| Invested Capital | $424,590,000 | $472,021,000 | $-84,538,000 | $-16,575,000 |
| Working Capital | $345,956,000 | $309,988,000 | $48,888,000 | $165,372,000 |
| Capital Lease Obligations | $30,528,000 | $30,396,000 | $34,697,000 | $37,763,000 |
| Total Capitalization | $424,590,000 | $472,021,000 | $-144,068,000 | $-18,658,000 |
| Treasury Stock | $46,467,000 | $46,467,000 | $5,977,000 | $563,000 |
| Additional Paid In Capital | $1,732,393,000 | $1,702,219,000 | $860,816,000 | $847,008,000 |
| Capital Stock | $404,000 | $396,000 | $83,000 | $80,000 |
| Common Stock | $404,000 | $396,000 | $83,000 | $80,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $7,793,000 | $39,917,000 | $14,275,000 | $18,175,000 |
| Long Term Capital Lease Obligation | $25,038,000 | $25,590,000 | $30,374,000 | $34,081,000 |
| Current Deferred Revenue | $42,936,000 | $15,741,000 | $16,735,000 | $14,436,000 |
| Current Capital Lease Obligation | $5,490,000 | $4,806,000 | $4,323,000 | $3,682,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $18,146,000 | $10,040,000 | $12,052,000 | $3,965,000 |
| Current Accrued Expenses | $10,696,000 | $9,455,000 | $6,626,000 | $10,189,000 |
| Investments And Advances | $25,701,000 | $0 | - | - |
| Net PPE | $46,007,000 | $49,342,000 | $54,850,000 | $59,535,000 |
| Accumulated Depreciation | $-48,162,000 | $-40,265,000 | $-35,489,000 | $-29,029,000 |
| Gross PPE | $94,169,000 | $89,607,000 | $90,339,000 | $88,564,000 |
| Leases | $14,050,000 | $13,749,000 | $13,785,000 | $12,234,000 |
| Construction In Progress | $900,000 | $6,028,000 | $2,334,000 | $1,612,000 |
| Other Properties | $62,115,000 | $61,972,000 | $66,226,000 | $67,212,000 |
| Machinery Furniture Equipment | $17,104,000 | $7,858,000 | $7,994,000 | $7,506,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $11,097,000 | $7,260,000 | $8,111,000 | $15,245,000 |
| Work In Process | $253,000 | $443,000 | $282,000 | $945,000 |
| Raw Materials | $8,631,000 | $13,041,000 | $12,140,000 | $16,866,000 |
| Other Short Term Investments | $66,712,000 | $126,146,000 | $63,191,000 | $84,475,000 |
| Goodwill | - | $111,297,000 | $106,317,000 | $106,251,000 |
| Inventories Adjustments Allowances | - | - | $-7,041,000 | $-11,583,000 |
| Line Of Credit | - | - | - | $0 |
| Buildings And Improvements | - | - | - | $43,500,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-82,646,000 | $-151,809,000 | $-46,118,000 | $-93,195,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-74,343,000 | $-143,454,000 | $-43,287,000 | $-89,370,000 |
| Cash Flow From Continuing Operating Activities | $-74,343,000 | $-143,454,000 | $-43,287,000 | $-89,370,000 |
| Operating Gains Losses | $-232,000 | $-632,000 | - | $73,800,000 |
| Investing Activities | ||||
| Capital Expenditure | $-8,303,000 | $-8,355,000 | $-2,831,000 | $-3,825,000 |
| Investing Cash Flow | $27,409,000 | $363,174,000 | $20,237,000 | $-88,127,000 |
| Cash Flow From Continuing Investing Activities | $27,409,000 | $363,174,000 | $20,237,000 | $-88,127,000 |
| Net Other Investing Changes | $-5,000,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-40,490,000 | $-5,414,000 | $-563,000 |
| Financing Cash Flow | $570,000 | $-102,616,000 | $-6,809,000 | $230,758,000 |
| Cash Flow From Continuing Financing Activities | $570,000 | $-102,616,000 | $-6,809,000 | $230,758,000 |
| Net Other Financing Charges | $-484,000 | $-1,004,000 | $-139,000 | $-12,758,000 |
| Net Common Stock Issuance | $0 | $-40,490,000 | $-5,414,000 | $-563,000 |
| Issuance Of Capital Stock | - | $0 | $0 | $225,000,000 |
| Net Preferred Stock Issuance | - | $0 | $0 | $225,000,000 |
| Preferred Stock Issuance | - | $0 | $0 | $225,000,000 |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-63,192,000 | $-2,083,000 | $-6,838,000 |
| Interest Paid Supplemental Data | $15,000 | $3,088,000 | $3,819,000 | $3,493,000 |
| End Cash Position | $123,296,000 | $168,818,000 | $52,499,000 | $82,324,000 |
| Beginning Cash Position | $168,818,000 | $52,499,000 | $82,324,000 | $29,467,000 |
| Effect Of Exchange Rate Changes | $842,000 | $-785,000 | $34,000 | $-404,000 |
| Changes In Cash | $-46,364,000 | $117,104,000 | $-29,859,000 | $53,261,000 |
| Proceeds From Stock Option Exercised | $1,054,000 | $2,070,000 | $827,000 | $917,000 |
| Common Stock Payments | $0 | $-40,490,000 | $-5,414,000 | $-563,000 |
| Net Issuance Payments Of Debt | $0 | $-63,192,000 | $-2,083,000 | $18,162,000 |
| Net Short Term Debt Issuance | $0 | $-63,192,000 | $-2,083,000 | $-6,838,000 |
| Short Term Debt Payments | $0 | $-63,192,000 | $-2,083,000 | $-6,838,000 |
| Net Investment Purchase And Sale | $40,712,000 | $92,881,000 | $23,068,000 | $-84,302,000 |
| Sale Of Investment | $179,000,000 | $349,000,000 | $117,964,000 | $53,000,000 |
| Purchase Of Investment | $-138,288,000 | $-256,119,000 | $-94,896,000 | $-137,302,000 |
| Net Business Purchase And Sale | $0 | $278,648,000 | $0 | $0 |
| Sale Of Business | $0 | $280,033,000 | $0 | $0 |
| Purchase Of Business | $0 | $-1,385,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-8,303,000 | $-8,355,000 | $-2,831,000 | $-3,825,000 |
| Purchase Of PPE | $-8,303,000 | $-8,355,000 | $-2,831,000 | $-3,825,000 |
| Change In Working Capital | $-44,978,000 | $-29,197,000 | $-1,972,000 | $-18,595,000 |
| Change In Other Working Capital | $-1,314,000 | $-4,143,000 | $884,000 | $-3,467,000 |
| Change In Other Current Liabilities | $-6,623,000 | $-10,047,000 | $-3,712,000 | $-9,091,000 |
| Change In Payables And Accrued Expense | $12,794,000 | $-12,160,000 | $7,801,000 | $1,337,000 |
| Change In Accrued Expense | $10,357,000 | $815,000 | $6,183,000 | $4,113,000 |
| Change In Payable | $2,437,000 | $-12,975,000 | $1,618,000 | $-2,776,000 |
| Change In Account Payable | $2,437,000 | $-12,975,000 | $1,618,000 | $-2,776,000 |
| Change In Prepaid Assets | $1,143,000 | $-1,929,000 | $862,000 | $33,000 |
| Change In Inventory | $-11,524,000 | $-9,879,000 | $-4,914,000 | $-8,470,000 |
| Change In Receivables | $-39,454,000 | $8,961,000 | $-2,893,000 | $1,063,000 |
| Changes In Account Receivables | $-1,361,000 | $8,967,000 | $-2,991,000 | $1,063,000 |
| Other Non Cash Items | $3,747,000 | $-18,422,000 | $4,803,000 | $4,890,000 |
| Stock Based Compensation | $29,613,000 | $31,732,000 | $13,123,000 | $14,880,000 |
| Unrealized Gain Loss On Investment Securities | $602,000 | $0 | $0 | - |
| Provisionand Write Offof Assets | $3,468,000 | $2,524,000 | $1,496,000 | $7,874,000 |
| Amortization Of Securities | $-2,644,000 | $-7,435,000 | $-1,261,000 | $-674,000 |
| Depreciation Amortization Depletion | $10,977,000 | $16,861,000 | $15,180,000 | $15,027,000 |
| Depreciation And Amortization | $10,977,000 | $16,861,000 | $15,180,000 | $15,027,000 |
| Amortization Cash Flow | $1,715,000 | $4,346,000 | $11,200,000 | $11,528,000 |
| Amortization Of Intangibles | $1,715,000 | $4,346,000 | $11,200,000 | $11,528,000 |
| Depreciation | $9,262,000 | $12,515,000 | $3,980,000 | $3,499,000 |
| Gain Loss On Investment Securities | $-232,000 | $-632,000 | - | $60,081,000 |
| Net Income From Continuing Operations | $-74,896,000 | $-138,885,000 | $-74,656,000 | $-190,098,000 |
| Issuance Of Debt | - | $0 | $0 | $25,000,000 |
| Income Tax Paid Supplemental Data | - | $607,000 | $801,000 | $309,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $25,000,000 |
| Long Term Debt Issuance | - | $0 | $0 | $25,000,000 |
| Asset Impairment Charge | - | $0 | $0 | $3,526,000 |
| Gain Loss On Sale Of Business | - | - | $0 | $13,719,000 |
| Short Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-23